{"id":15255,"date":"2025-04-22T11:04:04","date_gmt":"2025-04-22T09:04:04","guid":{"rendered":"https:\/\/www.impulso.es\/the-cdti-program-for-r-projects-linked-to-the-aerospace-and-health-pertes-remains-in-effect\/"},"modified":"2026-11-06T13:30:06","modified_gmt":"2026-11-06T11:30:06","slug":"the-cdti-program-for-r-projects-linked-to-the-aerospace-and-health-pertes-remains-in-effect","status":"publish","type":"post","link":"https:\/\/www.impulso.es\/en\/the-cdti-program-for-r-projects-linked-to-the-aerospace-and-health-pertes-remains-in-effect\/","title":{"rendered":"THE CDTI PROGRAM FOR R PROJECTS LINKED TO THE AEROSPACE AND HEALTH PERTES REMAINS IN EFFECT"},"content":{"rendered":"

[vc_row][vc_column width=”5\/6″][vc_empty_space el_class=”vc_hidden-sm vc_hidden-xs”]

THE CDTI PROGRAM FOR RD PROJECTS LINKED TO THE AEROSPACE AND HEALTH PERTES REMAINS IN EFFECT<\/h1>
<\/div>

CDTI has an open application period until 12\/31\/2025<\/h2><\/div>[vc_column_text css=”.vc_custom_1745312469999{margin-right: 20px !important;margin-left: 20px !important;padding-top: 20px !important;}”]We would like to remind you that CDTI still has an open application period for the RD PROJECTS LINKED TO THE AEROSPACE AND HEALTH PERTES<\/strong> program. The objective of this program is to finance individual RD projects<\/strong> aligned with these two areas<\/u><\/strong>:<\/p>\n

<\/p>\n

    \n
  • \n
      \n
    • AEROSPACE SECTOR<\/u><\/strong>: projects related to the design, development, manufacturing, operation, and maintenance of manned and unmanned aircraft, space vehicles, and propulsion systems, as well as the corresponding infrastructure necessary for their operation (such as airports, air navigation systems, launch bases, or satellite tracking stations) and for carrying out experimentation and testing tasks during their development phases. Also, the development of commercial services directly related to aeronautics and space infrastructure.<\/li>\n
    • VANGUARD HEALTH SECTOR<\/u><\/strong>: projects that pursue the promotion and protection of health through the development and incorporation of products, innovative procedures, and digital solutions that add value to the prevention, diagnosis, treatment, or rehabilitation of patients in a personalized manner.<\/li>\n<\/ul>\n

      We present the main characteristics of this program<\/u><\/strong>:<\/p>\n

      BENEFICIARIES:<\/u><\/strong><\/p>\n

      Companies <\/strong>(SMEs and Large Enterprises), Agricultural Transformation Societies, Cooperative Societies, Labor Societies, Public Business Entities, State Mercantile Societies, etc.<\/strong><\/p>\n

      TYPES OF PROJECTS:<\/u><\/strong><\/p>\n

        \n
      • Individual RD projects involving both industrial research and experimental development activities.<\/strong><\/li>\n
      • Certain project activities may be subcontracted<\/strong> to other companies or research organizations, such as universities, technology centers, singular scientific infrastructures (ICTS2), or public research bodies, among others.<\/li>\n
      • Not<\/u><\/strong> eligible for funding are actions that directly or indirectly cause harm to the environment:<\/u><\/strong>\n
          \n
        • Those related to fossil fuels<\/strong>, unless they concern the generation of electricity and\/or heat using natural gas, as well as the related transport and distribution infrastructure, provided they comply with Annex III of the Technical Guidance on the application of the DNSH principle.<\/li>\n
        • Those included within the EU ETS framework<\/strong> whose estimated greenhouse gas emissions are not below the relevant benchmarks.<\/li>\n
        • Those related to waste landfills and incinerators<\/strong> and to mechanical biological treatment plants<\/strong>.<\/li>\n
        • Those in which the long-term disposal of waste<\/strong> may cause harm to the environment<\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

          PROJECT REQUIREMENTS:<\/u><\/strong><\/p>\n

            \n
          • Incentive effect<\/strong>: the application must be submitted before investments begin.<\/li>\n
          • Minimum duration of 12 months<\/strong>, but never beyond 2026-12-31. <\/strong>With one or more milestones<\/strong>, the duration of each being from 9 to 18 months<\/strong>.<\/li>\n
          • Minimum budget:<\/strong> \u20ac175,000.<\/li>\n
          • At least 10% <\/strong>of the project budget must be funded with own resources.<\/strong><\/li>\n
          • Financing with funds from the Recovery and Resilience Facility – Compliance with the DNSH principle must be verified<\/strong>: a positive ex-ante report on DNSH compliance <\/strong>issued by an ENAC-accredited entity must be provided before signing the loan agreement with CDTI (maximum period: 3 months <\/strong>from grant approval).<\/li>\n
          • Incompatible <\/strong>with other grants.<\/li>\n
          • Alignment <\/strong>with one of the lines identified for the Vanguard Health sector or the Aerospace sector<\/strong>:<\/li>\n<\/ul>\n

            CUTTING-EDGE HEALTH AREA<\/u><\/strong>: to promote and protect health through the development and incorporation of products, innovative procedures and digital solutions that add value to the prevention, diagnosis, treatment or rehabilitation of patients in a personalised manner. Projects must align with one of the following points:<\/p>\n

              \n
            • Cross-cutting lines:<\/strong>\n
                \n
              • Maintain Spain’s leadership position in clinical research and retain investments from pharmaceutical companies.<\/li>\n
              • Invest in the development, digitalization and modernization of industrial capacity and facilitate the shift of production chains toward high-value-added diagnostic, therapeutic and rehabilitative innovation, expanding our industrial autonomy.<\/li>\n<\/ul>\n<\/li>\n
              • Strategic objectives:<\/strong>\n
                  \n
                • Promoting personalized precision medicine.<\/li>\n
                • Development of advanced therapies and other innovative drugs.<\/li>\n
                • Improvement of prevention, diagnosis, treatment, rehabilitation and health-oriented research based on the collection, processing, analysis and exploitation of data.<\/li>\n
                • Digital transformation of healthcare under secure cybersecurity conditions.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

                  AEROSPACE AREA<\/u><\/strong>: those relating to the design, development, manufacture, operation and maintenance of manned and unmanned aircraft, space vehicles and propulsion systems, as well as the corresponding infrastructure required for their operation (such as airports, air navigation systems, launch bases, or satellite tracking stations) and to carry out experimentation and testing tasks during their development phases. Also, the development of commercial services directly related to aeronautics and space infrastructure. The fields of action<\/strong> are as follows:<\/p>\n

                    \n
                  • In aeronautics:<\/strong>\n
                      \n
                    • Research and development aimed at increasing aircraft efficiency and significantly reducing polluting emissions from air transport, including airport infrastructure and air navigation systems that enable more efficient air traffic.<\/li>\n
                    • New developments of unmanned aircraft and the necessary software and hardware infrastructure for their safe operation in shared airspace.<\/li>\n
                    • On-board systems and equipment.<\/li>\n<\/ul>\n<\/li>\n
                    • In space:<\/strong>\n
                        \n
                      • Design of payloads related to environmental monitoring, quantum communications and security in international cooperation.<\/li>\n
                      • Strengthen Spanish technological capabilities for the commercial use of space (including New Space).<\/li>\n<\/ul>\n<\/li>\n
                      • Cross-cutting lines:<\/strong>\n